Graf R. Mark 4

What Happened
Mark R. Graf, a director of Harmony Biosciences (HRMY), was granted a derivative award on May 14, 2026: 21,872 shares reported as acquired (transaction code A) on the Form 4. The filing reports $0.00 as the acquisition price (no cash exchanged at grant); the award is described in the filing as a stock option that will vest in full on the earlier of May 14, 2027 or the date of the next annual meeting, subject to continued service.

Key Details

• Transaction date: 2026-05-14 (Form 4 filed 2026-05-18). Filing appears timely (filed within two business days).
• Transaction type/code: A = Award/Grant (derivative securities / stock option).
• Amount: 21,872 shares (derivative securities). Reported acquisition price: $0.00 (grant).
• Vesting: See footnote — vests in full on earlier of (i) May 14, 2027 or (ii) date of next annual meeting, subject to continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of a simultaneous sale or cashless exercise in this filing.

Context
This was a compensation grant (stock option award), not an open-market purchase or sale. Such awards are common to align directors’ incentives with shareholders but do not represent an immediate change in market-held shares unless and until options are exercised and shares are issued or sold. The filing’s $0.00 reflects that the recipient paid no cash at grant; the option’s exercise price and other terms beyond the vesting condition are not detailed in the excerpt provided.